<DOC>
	<DOCNO>NCT00012324</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know chemotherapy regimen effective liver cancer . PURPOSE : Randomized phase III trial compare effectiveness two different chemotherapy regimen treat patient recurrent unresectable liver cancer .</brief_summary>
	<brief_title>Nolatrexed Dihydrochloride Compared With Doxorubicin Treating Patients With Recurrent Unresectable Liver Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival patient unresectable recurrent hepatocellular carcinoma treat nolatrexed dihydrochloride v doxorubicin . - Compare time progression , time treatment failure , response rate patient treat regimen . - Compare probability survival 3 , 6 , 9 , 12 month patient treat regimen . - Compare safety clinical benefit regimens patient . - Compare response rate survival patient receive prior therapy prior therapy treatment two regimen . - Compare rate conversion unresectable resectable lesion patient treat regimen . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord CLIP score ( 0-1 v 2-3 ) Karnofsky performance status ( 60-70 % vs 80-100 % ) . Patients randomize one two treatment arm . - Arm I : Patients receive nolatrexed dihydrochloride IV continuously day 1-5 . - Arm II : Patients receive doxorubicin IV day 1 . Treatment continue arm every 3 week absence unacceptable toxicity disease progression . Patients follow every 2 month survival . PROJECTED ACCRUAL : Approximately 446 patient ( 223 per treatment arm ) accrue study within 12 month .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Nolatrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven presumptive diagnosis hepatocellular carcinoma Presumptive diagnosis base rise alphafetoprotein ( AFP ) level 2 assessment , CT scan MRI liver , spiral CT scan portal/splenic vein , biopsy evidence cirrhosis Unresectable recurrent disease prior surgical resection embolization therapy Fibrolamellar histology allow consider surgically unresectable base tumor size , extrahepatic involvement , multiple lobe involvement CLIP ( Cancer Liver Italian Program ) score less 4 Concurrent assignment transplantation list allow PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,200/mm^3 Platelet count least 80,000/mm^3 Hepatic : Bilirubin great 3.0 mg/dL ( except know Gilbert 's Syndrome ) AST great 5 time upper limit normal ( ULN ) PT great 1.5 time ULN Renal : Creatinine great 2.0 mg/dL Cardiovascular : No uncontrolled hypertension within past 3 month No unstable angina , symptomatic congestive heart failure , myocardial infarction within past 3 month No uncontrolled cardiac arrhythmia Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active bacterial infection HIV negative No AIDS No primary malignancy except carcinoma situ cervix urinary bladder nonmelanoma skin cancer No mental incapacitation psychiatric illness would preclude study participation No severe disease would preclude study participation Candidate placement central venous access device PRIOR CONCURRENT THERAPY : Biologic therapy : Prior biologic therapy allow No concurrent biologic therapy Chemotherapy : No prior IV doxorubicin except intraarterial administration locoregional therapy Endocrine therapy : Prior endocrine therapy allow No concurrent endocrine therapy Radiotherapy : Prior radiotherapy allow No concurrent radiotherapy Surgery : See Disease Characteristics Surgery allow previously unresectable lesion become resectable Recovered prior surgery No concurrent liver transplantation Other : No concurrent investigational market anticancer drug No concurrent therapy hepatocellular carcinoma No concurrent terfenadine , astemizole , cisapride may interrupt nolatrexed dihydrochloride administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>adult primary hepatocellular carcinoma</keyword>
</DOC>